Under 24 hours Prescription issued in under 24 hours if approved
Symptoms of depression or persistent low mood alongside changes in desire
The spray should be applied up to three hours before bedtime to maximize sleep benefits
Conditions that typically exclude GLP-1 candidacy - and that Omzo's clinical intake process is designed to screen for - include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), a history of pancreatitis, and known hypersensitivity to semaglutide or any component of the medication
DSIP is frequently researched for its relationship to sleep regulation pathways, circadian rhythm activity, neuroendocrine signaling, and recovery-related biological processes
This includes planning for what happens before a GLP-1 is started, alongside the medication, and after a GLP-1 is stopped